# China NMPA Drug Inspection - Jiangxi Zhangshu Gexuan Traditional Chinese Medicine Pieces Co., Ltd. - Chicken gizzard

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jiangxi-zhangshu-gexuan-traditional-chinese-medicine-pieces-co-ltd/0b041ce7-771d-4e87-89ba-7f340073c4f0/
Source feed: China

> China NMPA drug inspection for Jiangxi Zhangshu Gexuan Traditional Chinese Medicine Pieces Co., Ltd. published June 15, 2018. Drug: Chicken gizzard. On June 15, 2018, the National Medical Products Administration (NMPA) of China announced that 11 batches of drugs from e

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 44 of 2018 from the National Medical Products Administration regarding 11 batches of drugs that did not meet the requirements.
- Company Name: Jiangxi Zhangshu Gexuan Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2018-06-15
- Drug Name: Chicken gizzard
- Inspection Finding: Leachate does not meet regulations
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, recall products, and rectify the situation. Relevant provincial drug regulatory authorities will investigate and prosecute the illegal production and sale of counterfeit and substandard drugs in accordance with the "Drug Administration Law of the People's Republic of China" and publicly disclose the results of their investigations.
- Summary: On June 15, 2018, the National Medical Products Administration (NMPA) of China announced that 11 batches of drugs from eight different pharmaceutical companies failed to meet regulatory standards. The inspections, carried out by five provincial drug testing institutions, identified various quality control deficiencies across these products.Key violations included issues with product appearance and weight variation in Compound Platycodon grandiflorus Cough Tablets from Tonghua Zhongchen Pharmaceutical Co., Ltd. and Guizhou Sanrentang Pharmaceutical Co., Ltd. Anyang Lude Pharmaceutical Co., Ltd.'s Cold and Fever-Reducing Granules exhibited non-compliant content uniformity. Three traditional Chinese medicine manufacturers, including Jiangxi Zhangshu Tianqitang Traditional Chinese Medicine Pieces Co., Ltd. and Jiangxi Zhihetang Traditional Chinese Medicine Pieces Co., Ltd., produced Chicken Gizzard Lining with inadequate extractives. Shaanxi Ziguang Chenji Pharmaceutical Co., Ltd.'s Qipi Pills failed content determination, while Jilin Hengxing Technology Pharmaceutical Co., Ltd.'s Erythromycin Stearate Capsules had non-compliant moisture levels and dissolution rates.In response, regulatory authorities implemented immediate control measures such as product recalls, sales suspensions, and seizure of affected batches, requiring companies to rectify the identified issues. The NMPA mandated provincial drug regulatory authorities to thoroughly investigate these firms for illegal activities concerning substandard drug production and sales, under Articles 73, 74, and 75 of the Drug Administration Law of the People's Republic of China. Investigations and public disclosure of results are required within three months.

Company: https://www.globalkeysolutions.net/companies/jiangxi-zhangshu-gexuan-traditional-chinese-medicine-pieces-co-ltd/a908196d-ffd2-4858-ba1e-704b7ca5cc7d/